New Delhi, Aug. 6 -- Dabur India on Thursday said its domestic business remains unaffected despite receiving a warning letter from the US Food and Drug Administration (USFDA) over manufacturing deficiencies at its pharmaceutical facility in Silvassa. The company also confirmed that the plant continues to operate while it works with the regulator to address the observations.

The FMCG major said it has submitted a revised response to the USFDA outlining corrective measures to resolve the issues identified during the inspection.

"The Silvassa plant continues to be operational. This order concerns only a small part of our plant in relation to private label, which generates insignificant revenue for the company. Moreover, production of some ...